CRBP · XBRL financial data

Corbus Pharmaceuticals Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CRBP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	3,937	882	0	—	—	—
Research and development	98,267	36,445	16,137	31,168	32,222	70,095
General and administrative	28,480	20,425	18,699	13,910	16,499	15,215
Total operating expenses	126,747	56,871	39,835	45,077	48,721	85,310
Operating income (loss)	(122,810)	(55,989)	(39,835)	(45,077)	(48,721)	(85,310)
Interest expense	1,127	2,709	3,097	3,858	1,872	0
Other income (expense)	13,270	11,900	(49)	3,389	4,073	1,243
Income tax expense (benefit)	—	—	—	—	0	0
Net income (loss)	(111,269)	(45,640)	(42,347)	(44,603)	(40,209)	(78,537)
Earnings per share, basic USD per share	(1.42)	(0.37)	(10.15)	(10.31)	(3.68)	(5.90)
Earnings per share, diluted USD per share	—	(11.15)	(10.15)	(10.31)	(3.68)	(5.90)
Weighted average shares, basic thousands of shares	78,133	122,990	4,171	4,328	10,915	13,317
Weighted average shares, diluted thousands of shares	—	4,095	4,171	4,328	10,915	13,317

† Share count changed about 1/30 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (CRBP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	85,433	25,007	17,003	13,724	17,198	28,492
Short-term investments	—	72,641	42,194	7,182	131,864	134,777
Prepaid and other current assets	3,713	2,365	792	2,448	3,629	3,015
Total current assets	92,075	100,205	60,181	23,546	152,976	166,954
Property and equipment, net	4,068	2,393	1,614	973	385	159
Right-of-use asset	5,249	4,609	3,884	3,063	2,133	1,082
Total assets	102,295	107,730	66,312	28,272	155,879	168,195
Accounts payable	7,381	1,782	2,174	3,179	4,786	2,215
Accrued liabilities	22,005	10,093	5,999	11,031	5,426	16,844
Current portion of long-term debt	—	3,093	2,796	15,908	—	—
Total current liabilities	31,898	17,008	12,640	31,894	11,818	20,692
Long-term debt	18,029	15,636	15,984	0	—	—
Lease liability, non-current	7,093	5,956	4,675	3,239	1,633	0
Total liabilities	57,020	38,622	33,322	35,177	13,451	20,692
Accumulated deficit	(304,093)	(349,734)	(392,081)	(436,684)	(476,893)	(555,430)
Total stockholders' equity	45,275	69,108	32,990	(6,905)	142,428	147,503
Total liabilities and equity	102,295	107,730	66,312	28,272	155,879	168,195
Common shares outstanding (cover page) thousands of shares	124,937	125,243	4,171	10,493	12,232	17,736

† Share count changed about 1/30 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (CRBP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(111,269)	(45,640)	(42,347)	(44,603)	(40,209)	(78,537)
Stock-based compensation	12,458	9,480	5,720	3,470	6,145	6,288
Net cash from operating activities	(99,686)	(48,184)	(37,544)	(36,100)	(41,794)	(64,491)
Purchases of property and equipment	484	54	13	0	0	7
Net cash from investing activities	(484)	(73,417)	30,074	35,642	(121,310)	(1,641)
Proceeds from issuing common stock	142,201	62,586	—	244	182,058	77,426
Proceeds from long-term debt	18,756	—	1,382	—	—	—
Net cash from financing activities	154,875	60,823	(534)	(2,821)	166,578	77,426
Net change in cash	54,705	(60,777)	(8,004)	(3,279)	3,474	11,294

† Share count changed about 1/30 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Veru	23,880	not reported	(5,467)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Seres Therapeutics	17,528	593	(10,477)*	10.2M	1.1 quarters	Q3 FY26 10-QSep 30, 2026
Oncolytics Biotech	4,115	not reported	(8,138)*	127.5M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Lifevantage	14,920	42,377*	4,767*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Gyre Therapeutics	43,287	29,105	(16,728)*	111.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Volitionrx	2,800	399	(5,160)*	13.6M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Medicinova	25,416	458	(1,920)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.